LexisNexis Reed Tech
Explore our library of blogs, short videos, virtual event recordings and training topics
The FDA’s final rule standardizes National Drug Codes into a uniform 12-digit format beginning March 7, 2033. Pharmaceutical manufacturers, distributors, and healthcare stakeholders must prepare systems, labeling, serialization, and supply chain integrations during the transition period through 2036 to ensure compliance and avoid disruption.
The FDA has finalized guidance on promotional labeling and advertising for biologics, biosimilars, and interchangeable biosimilars, clarifying expectations to ensure communications are accurate, truthful, and not misleading across all media.
Understand how the US government shutdown affects FDA operations and how LexisNexis supports healthcare readiness.
Understand how the US government shutdown affects FDA operations and how LexisNexis supports healthcare readiness.
A government shutdown forces the FDA to scale back operations, delaying new drug and device approvals and slowing healthcare innovation. Learn what continues, what pauses, and why prolonged disruptions matter for patients and providers
Explore the key Pharmaceutical Innovators revealed in the latest Innovation Momentum report and their impact on the industry.
Learn how manufacturers can adopt FHIR to modernize labeling, enhance traceability, and meet evolving regulatory expectations.
Navigating drug and device regulations isn’t optional—it’s mission-critical. This Regulatory Survival Guide breaks down the complexities of global compliance, from FDA and EU MDR to Health Canada, UDI, and MoCRA. Whether you’re managing submissions or facing upcoming deadlines, use this FAQ to decode key terms, avoid costly risks, and stay ahead with expert-backed solutions like Compliance-as-a-Service (CaaS).
Global supply chain shifts can jeopardize regulatory labeling. Learn how LexisNexis Reed Tech helps manufacturers stay compliant through agile, localized labeling solutions.